Hajishengallis, George http://orcid.org/0000-0001-7392-8852
Reis, Edimara S
Mastellos, Dimitrios C
Ricklin, Daniel http://orcid.org/0000-0001-6140-0233
Lambris, John D
Article History
Received: 25 August 2017
Accepted: 24 September 2017
First Online: 16 November 2017
Competing interests
: J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (including third-generation compstatin analogs such as AMY-101), and is the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives); and J.D.L., G.H. and D.R. are inventors of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals.